All 3 Debates between George Freeman and Andrew Jones

Oral Answers to Questions

Debate between George Freeman and Andrew Jones
Tuesday 21st September 2021

(3 years, 1 month ago)

Commons Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Andrew Jones Portrait Andrew Jones (Harrogate and Knaresborough) (Con)
- View Speech - Hansard - - - Excerpts

4. What steps his Department is taking to establish the UK’s position as a world leader in science, research and innovation.

George Freeman Portrait The Parliamentary Under-Secretary of State for Business, Energy and Industrial Strategy (George Freeman)
- View Speech - Hansard - -

I thank my hon. Friend, who has been a distinguished Minister in the Treasury and the Department for Transport and a champion of innovation. As the Prime Minister has made clear, the Government are completely committed to unlocking this country’s global reach as a science superpower and an innovation nation. That is why we are committed to spending £14.9 billion this year on research and development, and to increasing the total R&D budget to £22 billion and 2.5% of GDP.

Andrew Jones Portrait Andrew Jones
- View Speech - Hansard - - - Excerpts

I thank my hon. Friend for that answer, and congratulate him. It is good to see him back at the Dispatch Box.

One of the largest employers in my constituency is Labcorp, a business that is at the heart of new medicine development both in the UK and across Europe and has played a role in the life science industry response to covid. It is considering UK expansion over the next five years at a number of sites across the UK. Will my hon. Friend meet me to discuss that opportunity, and also some of the obstacles that may get in the way of it, with a view to securing expansion in the UK as a whole but in Harrogate in particular?

George Freeman Portrait George Freeman
- View Speech - Hansard - -

I should be delighted to meet my hon. Friend soon to discuss that. Labcorp is a major global corporation whose investment in the new clinical pharmacology site is vital. It is in such companies that we need to be investing to drive private investment in research and development.

Oral Answers to Questions

Debate between George Freeman and Andrew Jones
Thursday 24th October 2019

(5 years ago)

Commons Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Andrew Jones Portrait Andrew Jones (Harrogate and Knaresborough) (Con)
- Hansard - - - Excerpts

After a widely supported and successful campaign against a relief road in Harrogate, the transport authority is now looking at a package of sustainable measures to take transport forward in the area. What support will the Government provide to North Yorkshire County Council and other such councils developing sustainable transport packages?

George Freeman Portrait George Freeman
- Hansard - -

My hon. Friend raises an excellent point. We are currently in the midst of talking to the Secretary of State for Housing, Communities and Local Government about a much more fundamental integration of housing and transport through the housing infrastructure fund. I will happily meet my hon. Friend to talk this through to make sure that it works for local places so that housing comes with proper transport.

Oral Answers to Questions

Debate between George Freeman and Andrew Jones
Thursday 11th September 2014

(10 years, 2 months ago)

Commons Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Andrew Jones Portrait Andrew Jones (Harrogate and Knaresborough) (Con)
- Hansard - - - Excerpts

What is the Department doing to make the UK a better place to do business for our already strong pharmaceutical sector? I am particularly thinking about encouraging clinical trials and bringing forward new medicines, which of course will benefit not only our economy, but patients receiving treatment in our NHS?

George Freeman Portrait George Freeman
- Hansard - -

My hon. Friend makes an important point. As a Minister in the Department of Health and in BIS, it is my job to make sure that we are building a landscape in which the UK is the best place to get quick access to patients, tissues, data and trials. Unless we can get innovations to patients more quickly, not only will we let them down, but, more importantly, we will not attract the investment into 21st century health technologies that we and our patients need.